Staphylococcus aureus is a significant human health threat, producing exotoxins called superantigens, which are responsible for a range of diseases. S. aureus superantigens are associated with food-borne illnesses, pulmonary disease, pneumonia, toxic shock syndrome, exacerbated atopic dermatitis, delayed wound healing, and infectious endocarditis. The objective of the proposed work is to use high-affinity probes against these toxins, engineered by ImmuVen, to develop ultrasensitive detection assays. The probes include soluble T cell receptor proteins (IMV01, IMV02, IMV03, and IMV04) engineered for very high-affinity binding to Staphylococcal enterotoxins SEB, SEC, TSST-1, and SEA, respectively. It is thought that there are about 185,000 cases of Staphylococcal food-borne illness in the United States, annually, resulting in around 1750 hospitalizations with a cost of $1.5 billion. The hypotheses of this Phase I application are that ImmuVen can develop a high affinity Vbeta protein that will bind SEA, the most important superantigen involved in Staphylococcal food-borne illness, and that this protein and the other already characterized soluble proteins can be used to develop a rapid multiplex assay for the detection of these Staphylococcal superantigens. The work will be performed in collaboration with Prof. David Kranz (University of Illinois), and Drs. Sandra Tallent and Jeffrey DeGrasse at the FDA.
The Specific Aims are: 1) To engineer a high affinity, soluble V? against SEA;2) To develop V?-based assays to detect SEA, SEB, SEC, and TSST-1. In Phase II work, ImmuVen will further develop these assays, toward both a standardized food detection platform, and a clinical diagnostic tool.

Public Health Relevance

Staphylococcus aureus is a significant human health threat, producing exotoxins called superantigens, which are responsible for a range of diseases. Staphylococcus aureus superantigens are associated with food-borne illness, pulmonary disease, pneumonia, TSS, exacerbated atopic dermatitis, delayed wound healing, and infectious endocarditis. It is thought that there are about 185,000 cases of Staphylococcal food-borne illness in the United States, annually, resulting in around 1750 hospitalizations with a cost of $1.5 billion. ImmuVen technology will be used to develop detection tools to identify Staphylococcal superantigens in a variety of samples.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI102432-01
Application #
8392577
Study Section
Special Emphasis Panel (ZRG1-IDM-V (12))
Program Officer
Hall, Robert H
Project Start
2012-08-01
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2014-07-31
Support Year
1
Fiscal Year
2012
Total Cost
$297,023
Indirect Cost
Name
Immuven, Inc.
Department
Type
DUNS #
829773550
City
Champaign
State
IL
Country
United States
Zip Code
61820
Sharma, Preeti; Wang, Ningyan; Chervin, Adam S et al. (2015) A Multiplex Assay for Detection of Staphylococcal and Streptococcal Exotoxins. PLoS One 10:e0135986
Sharma, Preeti; Wang, Ningyan; Kranz, David M (2014) Soluble T cell receptor V? domains engineered for high-affinity binding to staphylococcal or streptococcal superantigens. Toxins (Basel) 6:556-74
Sharma, P; Postel, S; Sundberg, E J et al. (2013) Characterization of the Staphylococcal enterotoxin A: V? receptor interaction using human receptor fragments engineered for high affinity. Protein Eng Des Sel 26:781-9